Human epidermal growth factor receptor (HER) 2–positive breast cancer represents 15–20% of all breast cancers,1,2 and up to 30–50% of patients with advanced or metastatic HER2-positive breast cancer will develop brain metastases (BrMs).3 This evidence concerns the gene ERBB2 and breast cancer.